BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

790 related articles for article (PubMed ID: 28939663)

  • 1. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.
    Zhou J; Liu M; Sun H; Feng Y; Xu L; Chan AWH; Tong JH; Wong J; Chong CCN; Lai PBS; Wang HK; Tsang SW; Goodwin T; Liu R; Huang L; Chen Z; Sung JJ; Chow KL; To KF; Cheng AS
    Gut; 2018 May; 67(5):931-944. PubMed ID: 28939663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
    Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS
    Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CCRK is a novel signalling hub exploitable in cancer immunotherapy.
    Mok MT; Zhou J; Tang W; Zeng X; Oliver AW; Ward SE; Cheng AS
    Pharmacol Ther; 2018 Jun; 186():138-151. PubMed ID: 29360538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell cycle-related kinase reprograms the liver immune microenvironment to promote cancer metastasis.
    Zeng X; Zhou J; Xiong Z; Sun H; Yang W; Mok MTS; Wang J; Li J; Liu M; Tang W; Feng Y; Wang HK; Tsang SW; Chow KL; Yeung PC; Wong J; Lai PB; Chan AW; To KF; Chan SL; Xia Q; Xue J; Chen X; Yu J; Peng S; Sung JJ; Kuang M; Cheng AS
    Cell Mol Immunol; 2021 Apr; 18(4):1005-1015. PubMed ID: 32879468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A CCRK-EZH2 epigenetic circuitry drives hepatocarcinogenesis and associates with tumor recurrence and poor survival of patients.
    Feng H; Yu Z; Tian Y; Lee YY; Li MS; Go MY; Cheung YS; Lai PB; Chan AM; To KF; Chan HL; Sung JJ; Cheng AS
    J Hepatol; 2015 May; 62(5):1100-11. PubMed ID: 25500144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and validation of Birc5 as a novel activated cell cycle program biomarker associated with infiltration of immunosuppressive myeloid-derived suppressor cells in hepatocellular carcinoma.
    Liu Y; Chen X; Luo W; Zhao Y; Nashan B; Huang L; Yuan X
    Cancer Med; 2023 Aug; 12(15):16370-16385. PubMed ID: 37326143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma.
    Sun H; Yang W; Tian Y; Zeng X; Zhou J; Mok MTS; Tang W; Feng Y; Xu L; Chan AWH; Tong JH; Cheung YS; Lai PBS; Wang HKS; Tsang SW; Chow KL; Hu M; Liu R; Huang L; Yang B; Yang P; To KF; Sung JJY; Wong GLH; Wong VWS; Cheng ASL
    Nat Commun; 2018 Dec; 9(1):5214. PubMed ID: 30523261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloid-intrinsic cell cycle-related kinase drives immunosuppression to promote tumorigenesis.
    Zhou J; Wang H; Shu T; Wang J; Yang W; Li J; Ding L; Liu M; Sun H; Wong J; Lai PB; Tsang SW; Ward SE; Chow KL; Sung JJ; Sze-Lok Cheng A
    iScience; 2023 Oct; 26(10):107626. PubMed ID: 37731616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells.
    Deng Y; Cheng J; Fu B; Liu W; Chen G; Zhang Q; Yang Y
    Oncogene; 2017 Feb; 36(8):1090-1101. PubMed ID: 27593937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
    Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
    J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell cycle-related kinase mediates viral-host signalling to promote hepatitis B virus-associated hepatocarcinogenesis.
    Yu Z; Gao YQ; Feng H; Lee YY; Li MS; Tian Y; Go MY; Yu DY; Cheung YS; Lai PB; Yu J; Wong VW; Sung JJ; Chan HL; Cheng AS
    Gut; 2014 Nov; 63(11):1793-804. PubMed ID: 24440987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma.
    Xiong Z; Chan SL; Zhou J; Vong JSL; Kwong TT; Zeng X; Wu H; Cao J; Tu Y; Feng Y; Yang W; Wong PP; Si-Tou WW; Liu X; Wang J; Tang W; Liang Z; Lu J; Li KM; Low JT; Chan MW; Leung HHW; Chan AWH; To KF; Yip KY; Lo YMD; Sung JJ; Cheng AS
    Gut; 2023 Sep; 72(9):1758-1773. PubMed ID: 37019619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SPTBN1 inhibits inflammatory responses and hepatocarcinogenesis via the stabilization of SOCS1 and downregulation of p65 in hepatocellular carcinoma.
    Lin L; Chen S; Wang H; Gao B; Kallakury B; Bhuvaneshwar K; Cahn K; Gusev Y; Wang X; Wu Y; Marshall JL; Zhi X; He AR
    Theranostics; 2021; 11(9):4232-4250. PubMed ID: 33754058
    [No Abstract]   [Full Text] [Related]  

  • 14. IL-1β-Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Up-regulating Programmed Death Ligand 1 and Colony-Stimulating Factor 1.
    He Q; Liu M; Huang W; Chen X; Zhang B; Zhang T; Wang Y; Liu D; Xie M; Ji X; Sun M; Tian D; Xia L
    Hepatology; 2021 Dec; 74(6):3174-3193. PubMed ID: 34288020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions between interleukin-6 and myeloid-derived suppressor cells drive the chemoresistant phenotype of hepatocellular cancer.
    Xu M; Zhao Z; Song J; Lan X; Lu S; Chen M; Wang Z; Chen W; Fan X; Wu F; Chen L; Tu J; Ji J
    Exp Cell Res; 2017 Feb; 351(2):142-149. PubMed ID: 28109867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2.
    Xie M; Lin Z; Ji X; Luo X; Zhang Z; Sun M; Chen X; Zhang B; Liang H; Liu D; Feng Y; Wang Y; Li Y; Liu B; Huang W; Xia L
    J Hepatol; 2023 Jul; 79(1):109-125. PubMed ID: 36907560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade.
    Kwong TT; Wong CH; Zhou JY; Cheng ASL; Sung JJY; Chan AWH; Chan SL
    JHEP Rep; 2021 Apr; 3(2):100224. PubMed ID: 33604533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD45
    Mao FY; Zhao YL; Lv YP; Teng YS; Kong H; Liu YG; Wu XL; Hao CJ; Chen W; Duan MB; Han B; Ma Q; Wang TT; Peng LS; Zhang JY; Cheng P; Su CY; Fu XL; Zou QM; Guo G; Guo XL; Zhuang Y
    Cell Death Dis; 2018 Jul; 9(7):763. PubMed ID: 29988030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell cycle-related kinase is a direct androgen receptor-regulated gene that drives β-catenin/T cell factor-dependent hepatocarcinogenesis.
    Feng H; Cheng AS; Tsang DP; Li MS; Go MY; Cheung YS; Zhao GJ; Ng SS; Lin MC; Yu J; Lai PB; To KF; Sung JJ
    J Clin Invest; 2011 Aug; 121(8):3159-75. PubMed ID: 21747169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.